Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists discover genetic switch that can prevent peripheral vascular disease in mice

29.07.2014

Millions of people in the United States have a circulatory problem of the legs called peripheral vascular disease. It can be painful and may even require surgery in serious cases. This disease can lead to severe skeletal muscle wasting and, in turn, limb amputation.


Working to develop a new treatment for peripheral vascular disease from left to right are UTHealth researchers Vikas Yadav, Ph.D., Sabina Lorca and Vihang Narkar, Ph.D.

Credit: The University of Texas Health Science Center at Houston (UTHealth)

At The University of Texas Health Science Center at Houston (UTHealth) Medical School, scientists tested a non-surgical preventative treatment in a mouse model of the disease and it was associated with increased blood circulation. Their proof-of-concept study appears in the journal Cell Reports.

Unlike previous studies in which other investigators used individual stimulatory factors to grow blood vessels, Vihang Narkar, Ph.D., senior author and assistant professor in the Department of Integrative Biology and Pharmacology at the UTHealth Medical School, identified and turned off a genetic switch that stifles blood vessel development.

"We discovered an inhibitory switch that degrades blood vessels," said Narkar, whose laboratory is in the UTHealth Center for Metabolic and Degenerative Diseases at The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases. "We were able to genetically turn it off to prevent peripheral vascular disease in a preclinical study."

Added Narkar, "Our next step will be to test this targeted treatment in models of other conditions that dramatically decrease circulation like diabetes and atherosclerosis."

Narkar said using individual growth factors to stimulate blood vessel growth often leads to the formation of leaky and non-functional blood vessels. "By turning off a genetic switch that acts as a roadblock for blood vessel growth, we were able to trigger and accelerate the natural process of blood vessel regeneration that involves a battery of growth factors," he said.

The switch is called peroxisome proliferator-activated receptor gamma co-activator 1 beta (PGC1beta) and could be a key to future treatments for additional conditions like cardiac myopathies, cancer and retinopathy.

###

Narkar's UTHealth co-authors are Vikas Yadav, Ph.D. (lead author), Antonios Matsakas, Ph.D., and Sabina Lorca. Narkar is on the faculty of The University of Texas Graduate School of Biomedical Sciences at Houston.

The study titled "PGC1beta activates anti-angiogenic program to repress neo-angiogenesis in muscle ischemia" received support from the American Heart Association (AHA#11SDG7600213), American Diabetes Association (ADA#1-13-BS-127) and Muscular Dystrophy Association (MDA#174408).

Robert Cahill | Eurek Alert!

Further reports about: UTHealth blood cardiac myopathie circulation conditions genetic switch peripheral vascular

More articles from Life Sciences:

nachricht Microbes in Central Park soil: If they can make it there, they can make it anywhere
01.10.2014 | University of Colorado at Boulder

nachricht Experts from CNIO discover shining cells responsible for developing tumors
30.09.2014 | Centro Nacional de Investigaciones Oncologicas (CNIO)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

BrainScaleS Conference: From Neurobiology to New Computer Architectures

25.09.2014 | Event News

17th European Health Forum Gastein: “Electing Health – The Europe We Want”

23.09.2014 | Event News

Future questions regarding data processing

22.09.2014 | Event News

 
Latest News

All directions are not created equal for nanoscale heat sources

01.10.2014 | Power and Electrical Engineering

Long-acting insulin is safer, more effective for patients with Type 1 diabetes

01.10.2014 | Health and Medicine

Microbes in Central Park soil: If they can make it there, they can make it anywhere

01.10.2014 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>